喘可治注射液对支气管哮喘免疫调控作用的临床与实验研究
|
摘要
研究目的
以哮喘免疫治疗的研究热点——Foxp3+ CD4+CD25+调节性T细胞的诱导为切入点,通过临床和实验两方面研究,探讨补肾温阳模式中药(喘可治注射液)在哮喘免疫调控中的作用及其机制。
研究方法
1.实验研究
将Balb/C小鼠随机分为3组：对照组、哮喘组、喘可治(CKZ)组。采取以OVA经腹腔注射致敏加滴鼻激发复制哮喘模型,喘可治组给予喘可治注射液腹腔注射治疗,对照组与哮喘组给予生理盐水腹腔注射。分别观察各组小鼠的肺部病理改变,检测支气管肺泡灌洗液(BALF)中EOS情况；流式细胞术检测脾淋巴细胞中Foxp3+CD4+CD25+T细胞/CD4+T细胞比例；免疫组化检测肺组织Foxp3蛋白的细胞表达情况；ELISA检测脾淋巴细胞上清中IL-4、IL-10和TNF-β水平。
2.临床研究
选取我院呼吸内科50例哮喘患者,随机分为对照组和观察组(CKZ组),对照组给予常规治疗,观察组在常规治疗基础上加予喘可治注射液肌注足三里(4m1/次,qd),疗程为7天。观测并记录治疗期间主症、PEF、总IgE、EOS、外周血T淋巴细胞亚群的变化。
研究结果
(一)实验部分
1.病理方面：喘可治注射液可降低哮喘小鼠气道周围炎症细胞尤其是EOS的浸润,减轻气道周围平滑肌增生。
2.流式细胞术检测方面：哮喘小鼠脾淋巴细胞中Foxp3+CD4+CD25+T细胞/CD4+T细胞比例低于对照组,喘可治注射液可显著提高此细胞比例。
3.免疫组化检测方面：哮喘小鼠肺组织Foxp3蛋白的表达低于对照组,喘可治注射液明显提高Foxp3的表达。
4.ELISA检测方面：哮喘小鼠脾淋巴细胞上清中存在高IL-4,低IL-10、TNF-β的失衡状态,喘可治注射液可纠正这种失衡的极化状态。
(二)临床部分
1.疗效方面：喘可治组综合疗效优于对照组,喘可治注射液对寒哮证和虚哮证的疗效优于热哮证,差异有统计学意义(P<0.05)。
2.实验室检查指标方面：喘可治注射液可降低哮喘患者外周血EOS及IgE水平,与对照组比较均有统计学差异；治疗前后PEF改善程度与对照组相近。
3.实验室检查指标方面：喘可治注射液治疗后,与对照组相比CD4+细胞明显减少,CD8+细胞显著增多,两组相比有统计学意义(P<0.05)
研究结论
1.哮喘存在Foxp3+CD4+CD25+调节性T细胞相对数量不足和功能缺陷,Thl和Th2之间的失衡参与了哮喘的发病机制；
2.喘可治注射液能有效减轻哮喘气道的变态反应炎症；
3.以喘可治注射液为代表的补肾温阳中药能抑制Th2细胞的增殖,促进Foxp3+CD4+CD25+调节性T细胞的活化和关健的转录因子Foxp3表达的增加而产生免疫耐受机制,抑制了炎症反应；
4.抑制性细胞因子IL-10和TNF-β可能参与了喘可治注射液诱导的Foxp3+CD4+CD25+调节性T细胞免疫抑制作用的机制。
Objective
Aim to investigate the immune regulation mechanism of Chuankezhi injection(CKZ) which is a Chinese medical model formula of reinforcing kidney and warming yang in the managment of bronchial asthma.
Methods
1.Animal Experiment:Mice were sensitized and challenged with ovalbumin (OVA) to establish allergic asthma-like model. To determine the contribution of Chuankezhi injection on airway allergic inflammation and immune regulation, we examined the BALF cell differentiated count, And lung histopathology, proportion of spleen Foxp3+CD4+CD25+Treg cells/CD4+T cells were measured by flowcytometry. Cytokines IL-4、IL-10 and TNF-βlevels in the cultured splenocytes supernatant were examined with ELISA. Foxp3 expression in lung was analyzed with immunohistochemistry.
2. Clinical study:50 mild or moderate asthmatic patients collected from the department of Respiratory Medicine, Guangdong Provincial hospital of TCM were randomized into control group and Chuankezhi (CKZ) group. The control group received conventional treatment. CKZ group received the intramuscular injection (4ml qd x 7days) and the conventional treatment as well. The changes of the primary symptoms、PEF values、IgE level, blood T cell subsets were recorded before and after the treatment.
Results
1. Animal Experiment Administration of Chuankezhi injection prevented the eosinophil accumulation in BALF in the lungs of asthma. CKZ group mice have a lower spleen Foxp3+CD4+CD25+Treg cells/CD4+T cells proportion compared with control group. Asthma group mice had higher IL-4 and lower IL-10、TNF-βlevels in the cultured splenocytes supernatant than control group. And Chuankezhi injection corrected the polarization respectively. Foxp3 expression in asthma mice lung was significantly lower than that in control group. And there was a higher level of Foxp3 due to the treatment with Chuankezhi injection.
2. Clinical study:The curative effects in 2 groups were significant (p<0.05) by statistical analysis, the effect in CKZ group was better than that in control group.Except for the major symptoms, CKZ group can lower EOS and IgE lever, correct the imbalance of CD4+ and CD8+ when compared with control group.2 groups can improve the peak expiratory flow rates. The comparison of PEFR after treatment were significant (p<0.05) by statistical analysis in the two group.
Conclusions
1. Insufficiency and dysfunction of Foxp3+CD4+CD25+Treg cell, as well as the imbalance between Thl and Th2 lymphocytes may play an important role in the pathogenesis of asthma.
2. Chuankezhi injection can alleviate allergic inflammation in the airway in asthma patients.
3. Chuankezhi injection inhibit the proliferation of Th2, and promote the activation of the Foxp3+CD4+CD25+ Treg cell and up-regulate the expression of the master transcription factor foxp3 to conduct immunotolerance.
4. Regulatory cytokines IL-10, TNF-βmay be involved in the regulatory mechanisms of Foxp3+CD4+CD25+Treg cells induced by Chuankezhi injection.
以哮喘免疫治疗的研究热点——Foxp3+ CD4+CD25+调节性T细胞的诱导为切入点,通过临床和实验两方面研究,探讨补肾温阳模式中药(喘可治注射液)在哮喘免疫调控中的作用及其机制。
研究方法
1.实验研究
将Balb/C小鼠随机分为3组：对照组、哮喘组、喘可治(CKZ)组。采取以OVA经腹腔注射致敏加滴鼻激发复制哮喘模型,喘可治组给予喘可治注射液腹腔注射治疗,对照组与哮喘组给予生理盐水腹腔注射。分别观察各组小鼠的肺部病理改变,检测支气管肺泡灌洗液(BALF)中EOS情况；流式细胞术检测脾淋巴细胞中Foxp3+CD4+CD25+T细胞/CD4+T细胞比例；免疫组化检测肺组织Foxp3蛋白的细胞表达情况；ELISA检测脾淋巴细胞上清中IL-4、IL-10和TNF-β水平。
2.临床研究
选取我院呼吸内科50例哮喘患者,随机分为对照组和观察组(CKZ组),对照组给予常规治疗,观察组在常规治疗基础上加予喘可治注射液肌注足三里(4m1/次,qd),疗程为7天。观测并记录治疗期间主症、PEF、总IgE、EOS、外周血T淋巴细胞亚群的变化。
研究结果
(一)实验部分
1.病理方面：喘可治注射液可降低哮喘小鼠气道周围炎症细胞尤其是EOS的浸润,减轻气道周围平滑肌增生。
2.流式细胞术检测方面：哮喘小鼠脾淋巴细胞中Foxp3+CD4+CD25+T细胞/CD4+T细胞比例低于对照组,喘可治注射液可显著提高此细胞比例。
3.免疫组化检测方面：哮喘小鼠肺组织Foxp3蛋白的表达低于对照组,喘可治注射液明显提高Foxp3的表达。
4.ELISA检测方面：哮喘小鼠脾淋巴细胞上清中存在高IL-4,低IL-10、TNF-β的失衡状态,喘可治注射液可纠正这种失衡的极化状态。
(二)临床部分
1.疗效方面：喘可治组综合疗效优于对照组,喘可治注射液对寒哮证和虚哮证的疗效优于热哮证,差异有统计学意义(P<0.05)。
2.实验室检查指标方面：喘可治注射液可降低哮喘患者外周血EOS及IgE水平,与对照组比较均有统计学差异；治疗前后PEF改善程度与对照组相近。
3.实验室检查指标方面：喘可治注射液治疗后,与对照组相比CD4+细胞明显减少,CD8+细胞显著增多,两组相比有统计学意义(P<0.05)
研究结论
1.哮喘存在Foxp3+CD4+CD25+调节性T细胞相对数量不足和功能缺陷,Thl和Th2之间的失衡参与了哮喘的发病机制；
2.喘可治注射液能有效减轻哮喘气道的变态反应炎症；
3.以喘可治注射液为代表的补肾温阳中药能抑制Th2细胞的增殖,促进Foxp3+CD4+CD25+调节性T细胞的活化和关健的转录因子Foxp3表达的增加而产生免疫耐受机制,抑制了炎症反应；
4.抑制性细胞因子IL-10和TNF-β可能参与了喘可治注射液诱导的Foxp3+CD4+CD25+调节性T细胞免疫抑制作用的机制。
Objective
Aim to investigate the immune regulation mechanism of Chuankezhi injection(CKZ) which is a Chinese medical model formula of reinforcing kidney and warming yang in the managment of bronchial asthma.
Methods
1.Animal Experiment:Mice were sensitized and challenged with ovalbumin (OVA) to establish allergic asthma-like model. To determine the contribution of Chuankezhi injection on airway allergic inflammation and immune regulation, we examined the BALF cell differentiated count, And lung histopathology, proportion of spleen Foxp3+CD4+CD25+Treg cells/CD4+T cells were measured by flowcytometry. Cytokines IL-4、IL-10 and TNF-βlevels in the cultured splenocytes supernatant were examined with ELISA. Foxp3 expression in lung was analyzed with immunohistochemistry.
2. Clinical study:50 mild or moderate asthmatic patients collected from the department of Respiratory Medicine, Guangdong Provincial hospital of TCM were randomized into control group and Chuankezhi (CKZ) group. The control group received conventional treatment. CKZ group received the intramuscular injection (4ml qd x 7days) and the conventional treatment as well. The changes of the primary symptoms、PEF values、IgE level, blood T cell subsets were recorded before and after the treatment.
Results
1. Animal Experiment Administration of Chuankezhi injection prevented the eosinophil accumulation in BALF in the lungs of asthma. CKZ group mice have a lower spleen Foxp3+CD4+CD25+Treg cells/CD4+T cells proportion compared with control group. Asthma group mice had higher IL-4 and lower IL-10、TNF-βlevels in the cultured splenocytes supernatant than control group. And Chuankezhi injection corrected the polarization respectively. Foxp3 expression in asthma mice lung was significantly lower than that in control group. And there was a higher level of Foxp3 due to the treatment with Chuankezhi injection.
2. Clinical study:The curative effects in 2 groups were significant (p<0.05) by statistical analysis, the effect in CKZ group was better than that in control group.Except for the major symptoms, CKZ group can lower EOS and IgE lever, correct the imbalance of CD4+ and CD8+ when compared with control group.2 groups can improve the peak expiratory flow rates. The comparison of PEFR after treatment were significant (p<0.05) by statistical analysis in the two group.
Conclusions
1. Insufficiency and dysfunction of Foxp3+CD4+CD25+Treg cell, as well as the imbalance between Thl and Th2 lymphocytes may play an important role in the pathogenesis of asthma.
2. Chuankezhi injection can alleviate allergic inflammation in the airway in asthma patients.
3. Chuankezhi injection inhibit the proliferation of Th2, and promote the activation of the Foxp3+CD4+CD25+ Treg cell and up-regulate the expression of the master transcription factor foxp3 to conduct immunotolerance.
4. Regulatory cytokines IL-10, TNF-βmay be involved in the regulatory mechanisms of Foxp3+CD4+CD25+Treg cells induced by Chuankezhi injection.
引文
[1]中华医学会呼吸病学分会哮喘学组.哮喘防治指南(哮喘的定义、诊断、治疗及教育和管理方案).中华内科杂志,2003；42(11)：817-822.
[2]许建中.中西医结合哮喘病学[M].北京：人民卫生出版社.第1版.
[3]陈灏珠.实用内科学[M].北京：人民卫生出版社.第11版.
[4]杜永成.哮喘的现代诊断与治疗[M].中国医药科技出版社.第1版.
[5]张晓星,吕祖铭.哮喘治疗的研究进展[J].泸州医学院学报,2005；28(1)：81-83.
[6]宋诵文.温肾健脾祛痰法控制哮喘复发30例[J].浙江中医杂志,1998：(1)：28-29.
[7]田止鉴.防喘胶囊防治哮喘176例[J].中国中医药信息杂志,2001；8(8)：49-50.
[8]李明星.参术汤治疗哮喘缓解期45例临床研究[J].吉林中医药,2006；26(3)：19-21.
[9]李向东.健脾益肺口服液治疗小儿哮喘缓解期50例[J].陕西中医,2003；24(6)：499-500.
[10]陈新开.玉屏风散和六味地黄汤治疗哮喘缓解期38例[J].辽宁中医学院学报,2000：2(1)：28.
[11]郝建新,柯新桥,周帧祥.支气管哮喘发作期证属热哮者为何仍加用补肾温阳之品治疗[J].中医杂志,1994；9：564
[12]张鹏.重用熟地治疗虚喘一得[J].中医杂志,1998；39(7)：398
[13]崔桂珍.温壮肾阳法治疗哮喘的体会[J].辽宁中医杂志,1998；2：18
[14]陈超,刘彦荣,李宁.补肾益肺法治疗哮喘病300例[J].中医函授通讯,1993：6：14
[15]谷峰.脏腑辨证防治支气管哮喘研究述评[J].中医函授通讯,1999；18(1)：22-24
[16]李明华,殷凯生,朱栓立.哮喘病学[M].北京：人民卫生出版社,1999,366
[17]马战平,朱梅,冯秀荣.支气管哮喘的中西医结合展望[J].陕西中医,2003：24(4)：337-339
[18]沈自尹.补肾法预防哮喘变态和非变态反应机理研究[J].中国中西医结合杂志,1989；(2)：82
[19]吴银根.温阳抗寒合剂治疗支气管哮喘98例[J].中国医药学报,1996：11(2)：33
[20]徐东.补肾防喘片与必可酮防治季节性哮喘发作的研究[J].中国中西医结合 杂志,1997：17(12)：721
[21]董党成.大剂量皮质类固醇吸入加补肾中药治疗激素依赖型哮喘的临床研究[J].中国中西医结合杂志,1994；14(8)：458
[22]左志雄,徐树槐.补肾法治疗支气管哮喘的研究概况[J].大理医学院学报,1999：8(1)：75-77
[23]Hansen G, Berry G, DeKruyff RH,Umetsu DT. Allergen-specific Thl cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation[J]. J Clin Invest 1999;103(2):175-183
[24]Gershon RK. A disquisition on suppressor T cells[J]. Transplant Rev 1975:26:170-185
[25]Gershon RK, Kondo K. Infectious immunologieal tolerance [J]. Immunology 1971;21(6):903-914.
[26]Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-hains(CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J]. J Immunol 1995;155(3):1151-1164
[27]DieekmannD, Plottner H, Berchtold S, Berger T, Sehuler G. Ex vivo isolation and characterization of CD4+CD25+T cells with regulatory properties from human blood[J].J Exp Med 2001; 193(11):1303-1310.
[28]Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25+regulatory cells in human peripheral blood[J].J Immunol 2001; 167(3):1245-1253
[29]Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4+CD25+T cells with regulatory properties isolated from peripheral blood[J].J Exp Med 2001:193(11):1285-1294.
[30]Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vahini V, Romagnani P,Maggi E, Romagnani S. Phenotype, localization,and mechanism of suppression of CD4+CD25+human thymocytes[J].J Exp Med 2002;196(3):379-387.
[31]Sakaguchi S. Nattlrally arising Foxp3-expressing CD4+CD25+regulatory T cells in imnlunological tolerance to self and non-self[J]. Nat Immunol 2005:6(4):345-352
[32]Fontenot JD, Rudensky AY. A well adapted regulatory cotrivance:regulatory T cell development and the forkhead family transcription factor Foxp3[J].Nat Immunol 2005;6(4):331-337,
[33]Hawrylowicz CM, Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma[J]. Nat Rev Immunol 2005; 5(4):271-283
[34]Schmidt-Weber CB, Blaser K. The role of the Foxp3 transcription factor in the immune regulation of allergic asthma[J].Curr Allergy Asthma ReP, 2005;5 (5):356-361
[35]Stoek P,DeKruyff RH, Umetsu DT. Inhibition of the allergic response by regulatory T cells[J]. Curr Opin Allergy Clin Imununol,2006;6(1):12-16.
[36]李明华,殷凯生,董竞成.哮喘病药物治疗学[M].北京：人民卫生出版社,2001,307
[37]Shirakawa T, Enomoto T, Shimazu S, et al. The inverse association between responses and atopic disorder[J]. Science,1997;275:77-79
[38]金美玲,龚燕,蔡映云等.草分枝杆菌疫苗治疗支气管哮喘的疗效及其免疫学效应[J].中国临床药学杂志,2002；11(3)：135-136
[39]刘乾中,周世良.卡介苗素对支气管哮喘患者免疫调节作用[J].中国临床药理学与治疗学,2002：7(6)：557-558
[40]薛建敏,徐永健,张珍祥.一氧化氮对哮喘患者IL-4、IL-5及γ干扰素表达的影响[J].中华内科杂志,1999：38(11)：772-773
[41]张宁,徐永健,张珍祥.一氧化氮对哮喘气道细胞因子表达的调控作用[J].中华微生物学和免疫学杂志,2003：23(6)：489-494
[42]胡晓光,李昌崇,干素蛾.哮喘Thl/Th2失衡及牛膝多糖和地塞米松的作用[J].浙江中西医结合杂志,2004：14(2)：77-78
[43]予桂英,刁万祥,潘虹.胸腺肽对支气管哮喘淋巴细胞亚群作用的观察[J].中国急救医学,1995：15(2)：29-30
[44]王通,曾耀英,俞渝.中药喘可治对小鼠胸腺细胞抗凋亡作用研究[J].辽宁中医杂志,2005：32(5)：490-491.
[45]王幼萍,曾耀英,肇静娴等.喘可治延长小鼠异基因移植皮片存活时间与CD4+CD25+调节性T细胞相关性研究[J].中国病理生理杂志,2005；21(4)：765-767.
[46]王幼萍,曾耀英,肇静娴.喘可治注射液对小鼠体外CD4+CD25+T细胞的影响[J].生命科学研究,2006：10(4)：338-341.
[47]张惠勇,倪伟,张金福等.喘可治注射液雾化吸入对调节支气管哮喘大鼠免疫失衡的实验研究[J].上海医学,2003：26(12)：904-906.
[48]肇静娴,曾耀英,王青等.喘可治注射液对人外周血单个核细胞Thl/Th2细胞因子谱的影响[J].中国免疫学杂志,2006；22(4)：356-359.
[49]张惠勇.喘可治治疗脾肾阳虚型哮喘缓解期的临床观察[J].上海中医药杂志,2002：36(4)：13-14.
[50]刘小虹,廖慧丽,梁直英.喘可治注射液治疗哮喘的临床观察[J].中药新药与 临床药理,2002：13(3)：146-147.
[51]Hayashi T, Adaehi Y, Hasegawa K, et aL. Less sensitivity for late airway inflammation in males than females in BALB/c mice[J]. Scand J lmmumol,2003;57(6):562.
[52]Shen HH, Ochkur SI, McCar ry MP, et al.A causative relationship exists between eosinophils and the development of allergic pulmonary pathologies in the mouse [J].J Immunol,2003;170(6):3296-3305.
[53]Stassen M, Jonuleit H, Muller C, et al. Differential regulatory capacity of CD25+T regulatory cells and preactivated CD25+T regulatory cells on development, functional activation, and proliferation of Th2 cells[J].J Immunol,2004;173:267-274
[54]Jonuleit H, Schmitt E, Kakirman H,et al. Infectious tolerance:human CD25+ regulatory T cells convey suppressor activity to conventional CD4+T helper cells[J].J Exp Med,2002; 196(2):255-26
[55]Kearley J, Barker JE, Robinson DS, Lloyd CM. Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent[J]. J Exp Med,2005;201:1539-1547
[56]von Herrath MG, Harrison LC. Antigen-induced regulatory T cells in autoimmunity[J]Nat Rev Immunol,2003;3(3):223-232.
[57]Peng Y,Laouar Y, Li M0. et al.TNF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+regulatory T cells responsible for protection against diabetes[J]. Proc Natl Acad Sci USA,2004;101(13)4572-4577
[58]Cobbld SP, Castejon R, Adams E, et al. Induction of Foxp3+Regulatory T Cells in the Periphery of T Cell Receptor Transgenic Mice Tolerized to Transplants[J]. J Immunol,2004;172(10):6003-601
[59]Asseman C, Mauze S, Leach M, et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal infiammation[J]T Exp Med,1999;190(7):995-1004
[60]Belkaid Y, Piccirillo CA,Mendez S, et al. CD4+CD25+regulatory T cells control Leishmania major persistence and immunity[J]. Nature,2002;420:502-507.
[61]国家中医药管理局.哮病的诊断依据、征候分类、疗效评定、中医病证诊断疗效标准[M].南京：南京大学出版社,1994,5.
[62]中华人民共和国卫生部.中药新药临床研究指导原则.1995.
[63]支气管哮喘的定义、诊断、严重度分级及疗效评定标准[J].中华结核和呼吸杂志,1993：16：5.
[64]陈佑邦.中医急诊医学[M].福建：福建科技出版社,1995.
[65]崔贵珍,朱正仑.温肾壮阳法治疗哮喘的体会[J].辽宁中医杂志,1988；2：18-19
[66]许德盛.温阳片防治支气管哮喘远期疗效观察[J].上海中医药杂志,1989：12：4
[67]崔贵珍,宋正合.温肾壮阳法治疗哮喘的体会[J].辽宁中医杂志,1988；12(2)：18-20.
[68]严桂珍,余传星,李希.益肾补肺平喘汤治疗支气管哮喘发作期42例临床观察[J].中国中医药科技,2000；7(6)：382
[69]沈白尹,陈瑜,黄建华等.EF延缓HPAT轴衰老的基因表达谱研究[J].中国免疫学杂志,2004；1(20)：16-18.
[70]史锁芳.平哮宁治疗支气管哮喘38例[J].南京中医学院学报,1994；5：45
[71]李明华,殷凯生,董竟成.哮喘病药物治疗学[M].北京：人民卫生出版社,第1版
[72]李明华,殷凯生,朱栓立.哮喘病学[M].北京：人民卫生出版社,第1版
[2]许建中.中西医结合哮喘病学[M].北京：人民卫生出版社.第1版.
[3]陈灏珠.实用内科学[M].北京：人民卫生出版社.第11版.
[4]杜永成.哮喘的现代诊断与治疗[M].中国医药科技出版社.第1版.
[5]张晓星,吕祖铭.哮喘治疗的研究进展[J].泸州医学院学报,2005；28(1)：81-83.
[6]宋诵文.温肾健脾祛痰法控制哮喘复发30例[J].浙江中医杂志,1998：(1)：28-29.
[7]田止鉴.防喘胶囊防治哮喘176例[J].中国中医药信息杂志,2001；8(8)：49-50.
[8]李明星.参术汤治疗哮喘缓解期45例临床研究[J].吉林中医药,2006；26(3)：19-21.
[9]李向东.健脾益肺口服液治疗小儿哮喘缓解期50例[J].陕西中医,2003；24(6)：499-500.
[10]陈新开.玉屏风散和六味地黄汤治疗哮喘缓解期38例[J].辽宁中医学院学报,2000：2(1)：28.
[11]郝建新,柯新桥,周帧祥.支气管哮喘发作期证属热哮者为何仍加用补肾温阳之品治疗[J].中医杂志,1994；9：564
[12]张鹏.重用熟地治疗虚喘一得[J].中医杂志,1998；39(7)：398
[13]崔桂珍.温壮肾阳法治疗哮喘的体会[J].辽宁中医杂志,1998；2：18
[14]陈超,刘彦荣,李宁.补肾益肺法治疗哮喘病300例[J].中医函授通讯,1993：6：14
[15]谷峰.脏腑辨证防治支气管哮喘研究述评[J].中医函授通讯,1999；18(1)：22-24
[16]李明华,殷凯生,朱栓立.哮喘病学[M].北京：人民卫生出版社,1999,366
[17]马战平,朱梅,冯秀荣.支气管哮喘的中西医结合展望[J].陕西中医,2003：24(4)：337-339
[18]沈自尹.补肾法预防哮喘变态和非变态反应机理研究[J].中国中西医结合杂志,1989；(2)：82
[19]吴银根.温阳抗寒合剂治疗支气管哮喘98例[J].中国医药学报,1996：11(2)：33
[20]徐东.补肾防喘片与必可酮防治季节性哮喘发作的研究[J].中国中西医结合 杂志,1997：17(12)：721
[21]董党成.大剂量皮质类固醇吸入加补肾中药治疗激素依赖型哮喘的临床研究[J].中国中西医结合杂志,1994；14(8)：458
[22]左志雄,徐树槐.补肾法治疗支气管哮喘的研究概况[J].大理医学院学报,1999：8(1)：75-77
[23]Hansen G, Berry G, DeKruyff RH,Umetsu DT. Allergen-specific Thl cells fail to counterbalance Th2 cell-induced airway hyperreactivity but cause severe airway inflammation[J]. J Clin Invest 1999;103(2):175-183
[24]Gershon RK. A disquisition on suppressor T cells[J]. Transplant Rev 1975:26:170-185
[25]Gershon RK, Kondo K. Infectious immunologieal tolerance [J]. Immunology 1971;21(6):903-914.
[26]Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-hains(CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J]. J Immunol 1995;155(3):1151-1164
[27]DieekmannD, Plottner H, Berchtold S, Berger T, Sehuler G. Ex vivo isolation and characterization of CD4+CD25+T cells with regulatory properties from human blood[J].J Exp Med 2001; 193(11):1303-1310.
[28]Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25+regulatory cells in human peripheral blood[J].J Immunol 2001; 167(3):1245-1253
[29]Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH. Identification and functional characterization of human CD4+CD25+T cells with regulatory properties isolated from peripheral blood[J].J Exp Med 2001:193(11):1285-1294.
[30]Annunziato F, Cosmi L, Liotta F, Lazzeri E, Manetti R, Vahini V, Romagnani P,Maggi E, Romagnani S. Phenotype, localization,and mechanism of suppression of CD4+CD25+human thymocytes[J].J Exp Med 2002;196(3):379-387.
[31]Sakaguchi S. Nattlrally arising Foxp3-expressing CD4+CD25+regulatory T cells in imnlunological tolerance to self and non-self[J]. Nat Immunol 2005:6(4):345-352
[32]Fontenot JD, Rudensky AY. A well adapted regulatory cotrivance:regulatory T cell development and the forkhead family transcription factor Foxp3[J].Nat Immunol 2005;6(4):331-337,
[33]Hawrylowicz CM, Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma[J]. Nat Rev Immunol 2005; 5(4):271-283
[34]Schmidt-Weber CB, Blaser K. The role of the Foxp3 transcription factor in the immune regulation of allergic asthma[J].Curr Allergy Asthma ReP, 2005;5 (5):356-361
[35]Stoek P,DeKruyff RH, Umetsu DT. Inhibition of the allergic response by regulatory T cells[J]. Curr Opin Allergy Clin Imununol,2006;6(1):12-16.
[36]李明华,殷凯生,董竞成.哮喘病药物治疗学[M].北京：人民卫生出版社,2001,307
[37]Shirakawa T, Enomoto T, Shimazu S, et al. The inverse association between responses and atopic disorder[J]. Science,1997;275:77-79
[38]金美玲,龚燕,蔡映云等.草分枝杆菌疫苗治疗支气管哮喘的疗效及其免疫学效应[J].中国临床药学杂志,2002；11(3)：135-136
[39]刘乾中,周世良.卡介苗素对支气管哮喘患者免疫调节作用[J].中国临床药理学与治疗学,2002：7(6)：557-558
[40]薛建敏,徐永健,张珍祥.一氧化氮对哮喘患者IL-4、IL-5及γ干扰素表达的影响[J].中华内科杂志,1999：38(11)：772-773
[41]张宁,徐永健,张珍祥.一氧化氮对哮喘气道细胞因子表达的调控作用[J].中华微生物学和免疫学杂志,2003：23(6)：489-494
[42]胡晓光,李昌崇,干素蛾.哮喘Thl/Th2失衡及牛膝多糖和地塞米松的作用[J].浙江中西医结合杂志,2004：14(2)：77-78
[43]予桂英,刁万祥,潘虹.胸腺肽对支气管哮喘淋巴细胞亚群作用的观察[J].中国急救医学,1995：15(2)：29-30
[44]王通,曾耀英,俞渝.中药喘可治对小鼠胸腺细胞抗凋亡作用研究[J].辽宁中医杂志,2005：32(5)：490-491.
[45]王幼萍,曾耀英,肇静娴等.喘可治延长小鼠异基因移植皮片存活时间与CD4+CD25+调节性T细胞相关性研究[J].中国病理生理杂志,2005；21(4)：765-767.
[46]王幼萍,曾耀英,肇静娴.喘可治注射液对小鼠体外CD4+CD25+T细胞的影响[J].生命科学研究,2006：10(4)：338-341.
[47]张惠勇,倪伟,张金福等.喘可治注射液雾化吸入对调节支气管哮喘大鼠免疫失衡的实验研究[J].上海医学,2003：26(12)：904-906.
[48]肇静娴,曾耀英,王青等.喘可治注射液对人外周血单个核细胞Thl/Th2细胞因子谱的影响[J].中国免疫学杂志,2006；22(4)：356-359.
[49]张惠勇.喘可治治疗脾肾阳虚型哮喘缓解期的临床观察[J].上海中医药杂志,2002：36(4)：13-14.
[50]刘小虹,廖慧丽,梁直英.喘可治注射液治疗哮喘的临床观察[J].中药新药与 临床药理,2002：13(3)：146-147.
[51]Hayashi T, Adaehi Y, Hasegawa K, et aL. Less sensitivity for late airway inflammation in males than females in BALB/c mice[J]. Scand J lmmumol,2003;57(6):562.
[52]Shen HH, Ochkur SI, McCar ry MP, et al.A causative relationship exists between eosinophils and the development of allergic pulmonary pathologies in the mouse [J].J Immunol,2003;170(6):3296-3305.
[53]Stassen M, Jonuleit H, Muller C, et al. Differential regulatory capacity of CD25+T regulatory cells and preactivated CD25+T regulatory cells on development, functional activation, and proliferation of Th2 cells[J].J Immunol,2004;173:267-274
[54]Jonuleit H, Schmitt E, Kakirman H,et al. Infectious tolerance:human CD25+ regulatory T cells convey suppressor activity to conventional CD4+T helper cells[J].J Exp Med,2002; 196(2):255-26
[55]Kearley J, Barker JE, Robinson DS, Lloyd CM. Resolution of airway inflammation and hyperreactivity after in vivo transfer of CD4+CD25+ regulatory T cells is interleukin 10 dependent[J]. J Exp Med,2005;201:1539-1547
[56]von Herrath MG, Harrison LC. Antigen-induced regulatory T cells in autoimmunity[J]Nat Rev Immunol,2003;3(3):223-232.
[57]Peng Y,Laouar Y, Li M0. et al.TNF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+regulatory T cells responsible for protection against diabetes[J]. Proc Natl Acad Sci USA,2004;101(13)4572-4577
[58]Cobbld SP, Castejon R, Adams E, et al. Induction of Foxp3+Regulatory T Cells in the Periphery of T Cell Receptor Transgenic Mice Tolerized to Transplants[J]. J Immunol,2004;172(10):6003-601
[59]Asseman C, Mauze S, Leach M, et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal infiammation[J]T Exp Med,1999;190(7):995-1004
[60]Belkaid Y, Piccirillo CA,Mendez S, et al. CD4+CD25+regulatory T cells control Leishmania major persistence and immunity[J]. Nature,2002;420:502-507.
[61]国家中医药管理局.哮病的诊断依据、征候分类、疗效评定、中医病证诊断疗效标准[M].南京：南京大学出版社,1994,5.
[62]中华人民共和国卫生部.中药新药临床研究指导原则.1995.
[63]支气管哮喘的定义、诊断、严重度分级及疗效评定标准[J].中华结核和呼吸杂志,1993：16：5.
[64]陈佑邦.中医急诊医学[M].福建：福建科技出版社,1995.
[65]崔贵珍,朱正仑.温肾壮阳法治疗哮喘的体会[J].辽宁中医杂志,1988；2：18-19
[66]许德盛.温阳片防治支气管哮喘远期疗效观察[J].上海中医药杂志,1989：12：4
[67]崔贵珍,宋正合.温肾壮阳法治疗哮喘的体会[J].辽宁中医杂志,1988；12(2)：18-20.
[68]严桂珍,余传星,李希.益肾补肺平喘汤治疗支气管哮喘发作期42例临床观察[J].中国中医药科技,2000；7(6)：382
[69]沈白尹,陈瑜,黄建华等.EF延缓HPAT轴衰老的基因表达谱研究[J].中国免疫学杂志,2004；1(20)：16-18.
[70]史锁芳.平哮宁治疗支气管哮喘38例[J].南京中医学院学报,1994；5：45
[71]李明华,殷凯生,董竟成.哮喘病药物治疗学[M].北京：人民卫生出版社,第1版
[72]李明华,殷凯生,朱栓立.哮喘病学[M].北京：人民卫生出版社,第1版